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The extent to which CD8 T cells specific for other antigens expand to compensate for the mutational loss
of the prominent DbNP366 and D
bPA224 epitopes has been investigated using H1N1 and H3N2 influenza A




 T cells were found in the spleen and in the inflammatory population recovered by
bronchoalveolar lavage from mice that were first given the NPPA H1N1 virus intraperitoneally and then
challenged intranasally with the homologous H3N2 virus. The effect was less consistent when this prime-boost
protocol was reversed. Also, though the quality of the response measured by cytokine staining showed some
evidence of modification when these minor CD8-T-cell populations were forced to play a more prominent part,
the effects were relatively small and no consistent pattern emerged. The magnitude of the enhanced clonal
expansion following secondary challenge suggested that the prime-boost with the NPPA viruses gave a
response overall that was little different in magnitude from that following comparable exposure to the
unmanipulated viruses. This was indeed shown to be the case when the total response was measured by
ELISPOT analysis with virus-infected cells as stimulators. More surprisingly, the same effect was seen




 sets gave no indication of compensatory expansion. A possible explanation is that novel, as yet
undetected epitopes emerge following primary exposure to the NPPA deletion viruses. These findings have
implications for both natural infections and vaccines.
Immune escape variants are a common feature of some
RNA virus infections (6, 16). Even though most such muta-
tional change is associated with the antibody response (20, 42),
effector CD8 T cells can supply the necessary selective pres-
sure. Individuals with subclinical human immunodeficiency vi-
rus (HIV) infection may suddenly show evidence of increased
viral load following the emergence of mutants that no longer
express a key peptide recognized by controlling CD8 T cells
(13, 14). Evidence of T-cell-induced in vivo variation is also
found experimentally with a model of chronic neurological
disease caused by mouse hepatitis virus (21). However, even
the small RNA viruses generally express a spectrum of immu-
nogenic peptides that can be presented in the context of one or
another of the four or more different major histocompatibility
complex class I (MHCI) glycoproteins expressed in any healthy
person or MHC heterozygous mouse (4, 17, 38). Why is it,
then, that there can be an apparent failure to compensate for
the loss of an immunodominant peptide and the associated
CD8-T-cell-mediated control?
The influenza A viruses vary rapidly under antibody-medi-
ated selection pressure (24), though they do not normally es-
tablish persistent infections in mammalian hosts. Experiments
with T-cell-receptor (TCR) transgenic mice have shown that
influenza virus escape variants can emerge in the face of what
is essentially a monoclonal CD8-T-cell response (26). This
may not be a common occurrence in nature, as influenza vi-
ruses can also be controlled by the humoral response in the
absence of CD8-T-cell effector function (10, 28, 31). Even so,
though neutralizing antibody would likely eliminate any escape
variants selected by the cytotoxic T lymphocytes (CTLs), the
internal proteins that tend to provide the peptide targets for
T-cell recognition can show evidence of naturally occurring
mutation (5). Thus, it is important to understand in this sce-
nario whether other epitopes would compensate for the mu-
tation and function to clear the virus from the site of infection.
Recent advances in technology with the influenza A viruses
have made it possible to generate mutations that disable pep-
tide binding in the groove of the MHCI glycoprotein (19),
allowing analysis of the question whether minor CD8-T-cell
responses can compensate for the loss of a major epitope.
The reverse genetics approach (18, 37) was used to generate
variants of PR8 (PR, H1N1) and HK (HK, H3N2) influenza A
viruses with substitutions in the nucleoprotein (NP366-374,
ASNENMETM) and acid polymerase (PA224-233, SSLENFRA
YV) peptides that bind the H2Db MHCI glycoprotein (3, 32).
These mutations resulted in the replacement of the asparagine
at the fifth position of both epitopes with glutamine (N5Q).
Viruses were thus generated with single mutations in NP or PA
and double mutations in NP and PA. These PR and HK mu-
tants (NP, PA, and NPPA) grow both in tissue culture
and in C57BL/6J (B6) mouse lung at titers comparable to those
found following infection with the wild-type (WT) viruses,
though they are much more likely to cause fatal infection in
antibody-negative MT mice (37). Furthermore, these mu-
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tants did not cause mortality in BALB/c (H2d) mice, as these
viruses were engineered to disrupt only the NP and PA pep-
tides that bind to H2Db (37). This panel of PRNP, PRPA,
and PRNPPA viruses was used in prime-boost experiments
(37) with the homologous HK variants to analyze the charac-
teristics of the secondary CD8-T-cell response to the residual
polymerase 1 (PB1703-711, SSYRRPVGI) determinant pre-
sented by H2Kb (4). There was some augmentation of
KbPB1703-specific T-cell numbers in mice that were first im-
munized intraperitoneally (i.p.) with the PR8NPPA virus
and then infected intranasally (i.n.) after a month or more with
the HKNPPA virus. However, the KbPB1703-specific CD8

set never compensated numerically for the loss of the CD8
DbNP366
 and CD8 DbPA224
 populations that predominate
following the WT HK-RG3PR-RG challenge.
This experimental approach (37) has now been extended to
look further at possible compensation by CD8 T cells specific
for other known, minor epitopes (8, 36), following secondary
challenge. The consequences of primary infection are pre-
sented for the first time, and the possibility that an initial
exposure to these deletion viruses modifies the response pro-
file following WT challenge is investigated. In addition, the
question is asked whether the quality of the CD8-T-cell re-
sponse to minor epitopes changes in the absence of the immu-
nodominant effector populations.
MATERIALS AND METHODS
Mice, viruses, and infection. Female B6 mice were purchased from the Jack-
son Laboratory (Bar Harbor, Maine), and CD4-T-cell-deficient MHC class
II/ mice (15) were bred at St. Jude Children’s Research Hospital. All were
held under specific-pathogen-free conditions at St. Jude Children’s Research
Hospital, and the B6 mice were first infected at 8 to 10 weeks of age. The
generation and preparation of WT PR and mutant (PRNP, PRPA, and
PRNPPA) recombinant viruses from the A/Puerto Rico/8/34 plasmids by
using the eight-plasmid reverse genetics system and the subsequent replacement
of the H1N1 PR8 hemagglutinin (H) and neuraminidase (N) plasmids (WT HK,
HKNP, HKPA, and HKNPPA) with those from the H3N2 A/Aichi/2/68
(HK) virus have been described previously (18, 37). Primed (PR variants i.p. at
108 50% egg infective doses [EID50]) and naı¨ve mice were first anesthetized by
i.p. injection of 2,2,2-tribromoethanol (Avertin) and then infected i.n. with 107
EID50 of the HK viruses (1). The mice were anesthetized again at time of
sampling and then exsanguinated by section of the axillary artery. The spleens
were removed, and inflammatory cell populations were recovered from the
infected respiratory tract by bronchoalveolar lavage (BAL).
Flow cytometry, tetramer staining, and peptide stimulation. Virus-specific
CD8-T-cell responses were analyzed by flow cytometry (11). Lymphocytes from
disrupted spleens or mediastinal lymph nodes (MLN) were enriched for CD8
T cells by incubation with monoclonal antibodies to CD4 (GK1.5) and MHC
class II glycoprotein (M5/114.15.2), followed by anti-rat and anti-mouse immu-
noglobulin G-coated magnetic beads (Dynal A.S., Oslo, Norway). This routinely
gave a 90% depletion of CD4-T-cell numbers when measured with a non-
cross-reactive monoclonal antibody (RM4-4) to CD4. Inflammatory cell popu-
lations recovered from the pneumonic lung by BAL were depleted of macro-
phages by incubation on plastic for 1 h at 37°C. The DbNP366 and DbPA224
tetramers were made by complexing H2Db with the immunogenic NP
(ASNENMETM) or PA (SSLENFRAYV) peptide (3, 32). The KbPB1703 and
KbNS2114 tetramers utilized H2Kb and the polymerase 1 (PB1, SSYRRPVGI) or
nonstructural protein 2 (NS2114-121, RTFSFQLI) peptide (4, 36). Lymphocytes
were incubated for 60 min at room temperature with the phycoerythrin-conju-
gated tetramers in phosphate-buffered saline–bovine serum albumin–azide fol-
lowed by anti-CD8-PerCP Cy5.5 (PharMingen, San Diego, Calif.). Other CD8
T cells were analyzed by the peptide stimulation-cytokine (PepC) assay. Lym-
phocytes were first incubated with 1 M NP, PA, PB1, NS2, matrix protein
(M1128-135, MGLIYNRM), or PB1-F262-70 (LSLRNPILV) peptide (8, 36) for 5 h
in the presence of 5 g of brefeldin A (Epicentre Technologies, Madison,
Wis.)/ml and then fixed and stained for CD8, gamma interferon (IFN-; PE-
XMG 1.2), and tumor necrosis factor alpha (TNF-; APC-MP6-XT22). The data
were acquired on a Becton Dickinson FACSCalibur and analyzed using
CELLQuest software (Becton Dickinson Immunocytometry Systems, San Jose,
Calif.).
ELISPOT analysis. The ELISPOT protocol was used to estimate the total size
of IFN--producing CD8-T-cell populations in spleen following stimulation
with virus-infected antigen-presenting cells (APCs). Plates were coated overnight
with 10 g of purified anti-IFN- antibody (BD Biosciences)/ml and then washed
four times and blocked for at least 30 min at 37°C with 200 l of complete
medium. Serial dilutions of purified, splenic CD8 T cells from virus-infected B6
mice were then plated with APCs generated by suspending (for 1 h at 37°C) naı¨ve
spleen cells from naı¨ve, uninfected B6 or MHC class II/ mice in 1 ml of
allantoic fluid from wtHKx31RG virus-infected hen eggs, followed by incubation
for a further 3 h at 37°C after the addition of 10 ml of complete medium. Cell
numbers were adjusted to plate 5  105 stimulator cells/well. The plates were
washed thoroughly after 48 h of incubation, biotin-conjugated anti-IFN- anti-
body was added at a concentration of 5 g/ml, and the reaction mixture was
incubated overnight. Streptavidin-alkaline phosphatase conjugate (Dako) was
then added at a dilution of 1:500 in 100 l for 1 h, washed, and developed with
a 5-bromo-4-chloro-3-indolylphosphate–nitroblue tetrazolium (BCIP-NBT) so-
lution until spots were visible. The plates were washed again, dried, and counted
on a Zeiss ELISPOT reader.
Data set and statistical analysis. Many of the data are expressed as virus-
specific CD8-T-cell numbers, which were calculated from the percentage of
cells staining with tetrameric reagents or IFN- (PepC assay) and the percentage
of CD8 and the total cell counts for the enriched spleen, MLN, or BAL
sample populations that were analyzed by flow cytometry. The results are gen-
erally for groups of five mice. The findings for those infected with the mutant
(NP, PA, and NPPA) viruses were compared (generally by Student’s t
test) with the numbers generated following exposure to WT virus. Significant
differences, P  0.05, are identified by an asterisk in the figures.
RESULTS
The basic aim of these experiments was to determine
whether the increase in numbers that we saw previously (37)
for the CD8 KbPB1703
 set in the absence of concurrent,
secondary CD8 DbNP366
 and CD8 DbPA224
 responses in
B6 (H2b) mice can be augmented by the expansion of other,
minor virus-specific CD8 populations. The analysis also asked
whether the quality of these minor responses changes when the
predominant CD8 DbNP366
 and CD8 DbPA224
 T cells
are not involved. A separate HK3PR prime and boost study
(data not shown) with theseNP,PA, andNPPA viruses
in BALB/c (H2d) mice confirmed that there was no difference
in the prevalence of T cells specific for the NP147-155 (TYQR
TRALV) peptide presented by H2Kd. This establishes that the
N5Q substitution that prevents binding of the ASNENMETM
peptide to H2Db modifies neither the immunogenicity of other
NP regions nor the basic pathogenesis of the infectious process
in the absence of the H2Db MHCI glycoprotein.
Analysis of the recall response. The compensatory clonal
expansion above the values for the WT HK3PR challenge
(solid bars, Fig. 1) that we saw previously for the KbPB1703-
specific set following the loss of CD8 DbNP366
 and CD8
DbPA224
 T cells in mice primed (PR) and boosted (HK) with
the variant (open bars, NP; diagonally striped bars, PA;
diamond-patterned bars,NPPA, Fig. 1) influenza A viruses
was found consistently for tetramer staining of the CD8 set in
spleen, BAL sample, and MLN populations analyzed on day 7
at the peak of the secondary response (Fig. 1C, F, and I). This
increase in CD8 KbPB1703
-T-cell numbers was still appar-
ent in the spleen on day 10 and day 30, though not in the BAL
sample or the MLN. The inflammatory process in the BAL
sample cells begins to resolve by day 10, while activated-mem-
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ory CD8 T cells present on day 10 and the few remaining cells
on day 30 are likely to have down-regulated expression of the
CD62L lymph node homing receptor and will thus tend to be
found in the spleen, where CD62L does not play a part in
lymphocyte localization (33). There was also a persistent in-
crease in the numbers of splenic CD8 DbPA224
 T cells in the
mice that were given the PRNP and HKNP viruses (Fig. 1B
and E). This means that, because the spleen contains a very
high proportion of the peripheral CD8-T-cell pool, the size of
both the CD8 KbPB1703
 and CD8 DbPA224
 memory pop-
ulations is substantially increased (Fig. 1B and C) over the
values found in the WT HK3PR mice. By contrast, no signif-
icant change in magnitude was found at any time point for the
immunodominant CD8 DbNP366
 set in the HKPA3
PRPA challenge group (Fig. 1A, D, and G).
This analysis of CD8 KbPB1703
-T-cell prevalence by tet-
ramer staining (Fig. 1) was done in parallel with a peptide
stimulation–IFN- (PepC) study that added the capacity to
measure the KbPB1703-, K
bNS2114-, and K
bM1128-specific re-
sponses (Table 1; Fig. 2). The numbers of spleen memory T
cells specific for all epitopes were 1.0% at 8 weeks after i.p.
priming with the PR viruses (day 0, Table 1). The smallest
values were consistently found for the CD8 populations re-
sponding to the NS2114-121 and M1128-135 peptides, reinforcing
the impression that KbNS2114 and K
bM1128 are indeed minor
epitopes (day 0, Table 1).
The spleen response to KbM1128 was minimal throughout
and was not significantly increased (over the WT HK3PR
challenge) for the mutant viruses (days 7 to 30, Table 1).
However, though stimulation with the NS2114-121 peptide
tended to elicit relatively small numbers of CD8 T cells in
mice primed and boosted with the WT viruses, the KbNS2114-
specific sets found at all time points for the
HKNPPA3PRNPPA challenge were at least compa-
rable in size to the KbPB1703-specific populations (Table 1).
Furthermore, even in the WT HK3PR mice, substantial num-
bers of memory KbNS2114-specific T cells were found on day 30
(Table 1).
The same was true when we looked at the KbNS2114- and
KbPB1703-specific sets in the day 7 BAL sample populations
(Fig. 2A and B). Both were consistently and substantially in-
creased in number for the mice given the mutant viruses. The
profile for KbM1128 was similar, but the T-cell numbers were 5
to 10 times lower than those found for the other epitopes, and
the counts were also more variable (Fig. 2C). The decision was
thus taken not to pursue the KbM1128 analysis further, though
FIG. 1. Extent of compensation by CD8 DbPA224
 and CD8 KbPB1703
 T cells in mice primed and challenged with the mutant viruses. The
B6 mice were infected i.p. (108 EID50) with PR (H1N1) and challenged i.n. (10
7 EID50) with HK (H3N2) RG (solid bars) and NP (open bars),
PA (diagonally striped bars), and NPPA (diamond-patterned bars) mutant viruses. Spleen (A to C), BAL sample (D to F), and MLN (G to
I) populations were sampled on day 0 (spleen only, at 8 weeks after i.p. priming), day 7, day 10, and day 30 (spleen only) after i.n. challenge. The
numbers of virus-specific CD8 T cells were calculated from total cell counts, and percent values were determined by staining with the DbNP366
(A, D, and G), DbPA224 (B, E, and H) and K
bPB1703 (C, F, and I) tetramers. It is important to note that the scales for the y axis differ, reflecting
the number of cells recovered from the site sampled. The results are expressed as means standard deviations, and statistical significance (relative
to the HK-WT challenge) was determined by Student’s t test (, P  0.05, n 	 5).
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we did proceed to make the KbNS2114 tetramer. In a further
experiment, tetramer analysis of the secondary response to
KbNS2114 on day 10 after priming and challenge with the
mutant and WT viruses (Fig. 3) confirmed what was seen
previously with the IFN- study (Table 1; Fig. 2). Overall,
there seems to be a good measure of compensation by the
expansion of other epitope-specific CD8-T-cell populations
in the secondary HKNPPA3PRNPPA response.
Reversing the prime-boost conditions. The experimental
protocol was then varied by first giving the HK viruses i.n.,
followed 30 days later by i.p. challenge with a high dose of the
PR viruses (Table 2). Changing from PR i.p.3HK i.n. to HK
i.n.3PR i.p. reversed the sequence of lytic and nonlytic infec-
tion in this prime-boost strategy. Though there is substantial
replication of the virus in the lung and upper airways following
i.n. challenge, virus given i.p. is thought to induce only a single
cycle of protein synthesis with little (if any) virus production
and consequent infection of other cells. The difference reflects
the fact that cleavage of the influenza virus hemagglutinin to
make mature virus requires the involvement of a protease that
is restricted in distribution to the respiratory epithelium (22,
40). This change in regimen would thus limit the availability of
the antigen in the secondary challenge with the PR viruses.
Again, the response to KbM1128 was minimal, while the re-
sponses to KbPB1703 and K
bNS2114 were significantly en-
hanced in the mice given the mutant viruses (Table 2).
Primary response. The experiments so far (37) (Tables 1
and 2; Fig. 1 to 3) focused on the recall of virus-specific CD8-
T-cell memory, without presenting a systematic analysis of
what happens after primary i.n. exposure to the WT HK,
HKNP, HKPA, and HKNPPA viruses. Unlike the sit-
uation following secondary challenge (Fig. 1 to 3; Table 1),
there was no enhancement of CD8 KbPB1703
- or CD8
KbNS2114-T-cell numbers at the peak of the primary response
in spleen on day 10 or in the early stage of memory on day 30
(Fig. 4A to D). This was also true for the BAL sample cells on
day 10 (Fig. 4E). The compensatory effect (Fig. 1 to 3; Table 1)
found for the recall response following i.n. challenge with the
homologous, mutant HK and PR viruses was thus not seen for
these individual epitope-specific sets following primary infec-
tion (Fig. 4).
Challenge with WT virus. The question was then asked
whether priming with the mutant viruses in any way modifies
the response following a WT challenge, a situation that would
occur following natural infection if such viruses were being
used in a vaccination strategy. Mice were first exposed i.p. to
the panel of PR viruses. All were later infected i.n. with WT
HK virus. In general, the CD8 KbPB1703
 response in the
WT HK-infected mice that had been primed with the PRNP,
PRPA, and PRNPPA viruses was not significantly in-
creased over that found for the WT HK3PR group (Table 3).
This is in accord with the observation that priming with the
mutant viruses does not either increase the magnitude of the
primary response (Fig. 4) or result in persistent memory (day
0, Fig. 1) of the KbPB1703 epitope. The number of CD8

KbNS2114
 T cells in spleen was, however, significantly en-
hanced in the PRNPPA mice challenged i.n. with the WT
HK virus (last row, Table 3), but the counts were still small
compared with the secondary response to DbNP366 in the mice
primed with WT PR and PRPA (DbNP366 epitope, Table 3).
However, though a contemporary comparison was not done in
age-matched, naı¨ve mice, the primary responses to both
DbNP366 and D
bPA224 in the PRNP, PRPA, and
PRNPPA-primed mice looked to be small (compare re-
sults in Table 3 and Fig. 4), suggesting that secondary re-
sponses to both major and minor epitopes can diminish the
magnitude of a concurrent primary response.
Quality of the compensatory secondary response. The anal-
ysis of quality is based on the cytokine expression profiles
following short-term peptide stimulation (23, 29). The two
TABLE 1. Analysis of IFN- CD8 T cells from spleen in a secondary response following homologous challengea
Day Virus
% IFN- CD8 T cells (mean  SD)
NP PA PB1 NS2 M1
0 WT 0.6 0.1 0.3  0.08 0.4 0.1 0.07  0.04 0.01 0.02
NP 0.02  0.03* 0.24 0.07 0.3 0.15 0.07 0.03 0.01  0.02
PA 1.0  0.1 0.01  0.03* 0.15 0.05 0.08 0.05 0.01  0.01
NPPA 0.04  0.03* 0.02 0.03* 0.16 0.1 0.08  0.06 0.02  0.02
7 WT 10.9 0.4 1.0  0.5 1.5  0.6 0.5  1.3 0.14  0.07
NP 0.2  0.1* 2.7  1.0 5.6  1.8* 1.7 0.8 0.17  0.06
PA 13.4  4.9 0.5  0.09* 4.3 0.9* 3.1 1.3* 0.16  0.15
NPPA 0.2  0.06* 0.4 0.3* 3.8 1.0* 4.69 1.8* 0.48  0.40
10 WT 15.2 6.1 1.3  0.1 2.3  1.0 0.9  0.2 0.05  0.02
NP 0.2  0.1* 4.1  0.8* 10.0 2.9 4.5  0.7* 0.3 0.2*
PA 13.4  1.5 0.1  0.09* 6.2 2.0 4.8  1.0* 0.4 0.4
NPPA 0.03  0.01* 0.1 0.1* 3.4 0.7 4.8  1.3* 0.3 0.2
30 WT 17.5 9.0 2.0  0.8 3.1  1.3 1.7  1.0 0.07  0.05
NP 0.1  0.02* 4.9 1.7* 9.3 1.5* 3.7 2.3* 0.05  0.04
PA 14.6  4.7 0.5  0.1* 4.1 2.0 1.3  0.9 0.05  0.03
NPPA 0.1  0.02* 0.3 0.1* 4.7 2.6 4.6  1.3* 0.2 0.1
a Ten-week-old, female B6 mice were primed i.p. with 108 EID50 of PR8 WT and mutants per mouse. The mice were challenged i.n. with homologous X31 viruses
at 107 EID50 per mouse. Spleens were harvested on days 0 (8 weeks after priming), 7, 10, and 30, and the IFN- assay was performed as described in Materials and
Methods. The significant differences from the WT are indicated as * (P 
 0.05).
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measures were the percent TNF- cells within the CD8
IFN- cell set (Fig. 5) and the intensity of IFN- (Fig. 6A to
D) and TNF- (Fig. 6E to H) staining determined as mean
fluorescence intensity (MFI). The MFI value can be consid-
ered to reflect the magnitude of peptide-induced cytokine pro-
duction. The great majority of the KbNS2114- and K
bPB1703-
specific CD8 IFN- T cells recovered from the spleen and
BAL fluid compartments of secondarily challenged mice were
found to produce TNF- (Fig. 5). This profile was not substan-
tially modified for the mutant viruses, though it was consis-
tently the case that the prevalence of TNF- cells in spleen
(Fig. 5A and C) was at maximum frequency on day 30, in
accord with previous observations on the maturation of “func-
tional avidity” with time (23, 30). The values for the BAL cells
recovered from the respiratory tract, the site of high antigen
load in this influenza model, were always close to maximum
frequency (Fig. 5C and D).
The intensity of MFI staining was significantly higher for
spleen cells recovered on day 7 from mice given some of the
deletion viruses (day 7, Fig. 6A and B), but the effects were not
large and were not mirrored by the profiles for TNF- (day 7,
Fig. 6E and F). The MFI values for TNF- (but not IFN-)
then fell substantially on day 10 (day 10, Fig. 6; compare panels
E and F and panels A and B), which could reflect that TNF-
high cells are being recruited to the virus-infected lung. The
intensity of staining was more than restored by day 30 (Fig. 6E
and F), though the CD8 KbPB1703
 memory T cells from
mice given the mutants were consistently making less cytokine
than those induced by the prime-boost with the WT viruses




 IFN- T cells to the respiratory tract of virus sec-
ondarily challenged mice. This is the same experiment shown in Fig. 1.
Individual BAL samples were stimulated with 1 M concentrations of
the PB1703-711 (A), NS2114-121 (B), and M1128-135 (C) peptides for 5 h
and stained for IFN- expression (PepC assay). The numbers of
IFN- CD8 T cells were calculated and expressed as means 
standard deviations. Differences from the WT group are indicated by
an asterisk (P  0.05, by Student’s t test).
FIG. 3. Tetramer analysis of the KbNS2114-specific set in spleen
and BAL fluid populations from secondarily challenged mice. The i.p.
priming with PR viruses and i.n. challenge with HK viruses were done
exactly as described in the legend to Fig. 1, and lymphocyte popula-
tions were sampled on day 10 after homologous challenge. The results
(means  standard deviations, n 	 5) are expressed as the percentage
of cells staining (A) and the numbers of epitope-specific cells (B).
Significant differences from the WT group are indicated by an asterisk
(P  0.05).
TABLE 2. Characteristics of the response in mice primed i.n. and
challenged with WT and mutant virusesa
Virus
% IFN- CD8 T cells (mean  SD)
NP PA PB1 NS2 M1
WT 7.4  3.2 0.7  0.3 1.4  0.5 0.3  0.1 0.3  0.5
NP 0.01  0.01* 4.9  1.6* 7.9  1.6* 2.97  0.9* 0.5  0.4
PA 6.5  0.8 0.1  0.03* 3.4  0.9* 2.76  1.1* 0.3  0.09
NPPA 0.04  0.03* 0.09  0.06* 4.8  1.2* 2.97  1.1* 0.7  0.2
a B6 mice were primed i.n. with 106 EID50 of HK WT and mutants (NP,
PA, and NPPA). Viruses were then challenged 30 days later i.p. with 108
EID50 of the homologous PR viruses. The spleens were harvested on day 10 and
analyzed by PepC assay as described in Materials and Methods. Significant
differences from the HK-WT are indicated as * (P 
 0.05).
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(day 30, Fig. 6A and E). However, the same effect was not seen
for the CD8 KbNS2114 set (day 30, Fig. 6B and F). The most
striking finding for the inflammatory CD8 T cells recovered
by BAL was that the intensity of both IFN- and TNF-
staining on day 7 was greatest in the mice given the
HKPA3PRPA challenge (day 7, Fig. 6C, D, G, and H),
while the highest levels of both cytokines for CD8 KbPB1703

(but not CD8 KbNS2114
) T cells recovered from the resolv-
ing response on day 10 were found for the mice given the
mutant NP viruses (day 10, Fig. 6; compare panels C and G and
panels D and H). Overall, there was no substantial change in
the quality of the acute response or memory for these minor
T-cell populations expanded in the absence of the major sub-
sets.
Extent of compensation in primary and secondary re-
sponses. The findings from the tetramer and IFN- PepC
assays indicated that the size of the residual epitope-specific
CD8-T-cell populations increased following secondary (Ta-
bles 1 and 2; Fig. 1 to 3), but not primary (Fig. 4), challenge
with theNPPA viruses. The data presented in part in Table
1 and Fig. 2 were thus used to estimate the total size of the
secondary CD8-T-cell response (Fig. 7), the aim being to
determine the overall extent of compensation while at the
same time addressing the possibility that T cells specific for
some other, substantial epitope are not being measured. The
total CD8-T-cell counts in the HKNPPA3PRNPPA
group were significantly increased for day 7 in the spleen and
BAL sample (Fig. 7A and B), while the opposite effect was
seen for the relative prevalence (percentages) of virus-specific
cells in the day 7 and day 10 BAL sample populations (Fig.
7D). Overall, it seemed that the compensation effect in the
secondary response was partial.
It is, however, also possible that other minor epitopes (41)
are being expanded in the HKNPPA3PRNPPA re-
sponse. ELISPOT analysis after stimulation with virus-infected
cells was thus used to estimate the total size of both primary
(HK viruses i.n.) and secondary (PR viruses i.p. and then HK
viruses i.n.) virus-specific CD8-T-cell responses in spleen
(Fig. 8). Though ELISPOT analysis with virus-infected APCs is
generally less sensitive than the flow-cytometric PepC assays,
the results indicated that the level of both primary (Fig. 8A)
and secondary (Fig. 8B) response made by CD4-depleted vi-
rus-immune spleen cells following stimulation with HK-in-
fected stimulators was no different for the WT RG and
NPPA viruses. This was also true when MHC class II/
APCs were used to obviate any possibility that the result was
confounded by residual CD4-T-cell responders, though the
level of stimulation was somewhat lower, reflecting, perhaps,
that dendritic cells from CD4-T-cell-deficient mice do not
FIG. 4. Characteristics of the primary virus-specific CD8-T-cell response. The B6 mice were infected i.n. with 107 EID50 of the HK variants.
The spleen (A to D) and BAL fluid (E) populations were sampled on day 10 at the peak of the acute response, and the early phase of memory
was measured on day 30 (A to D) for the spleen. The numbers of tetramer CD8 T cells were calculated from total cell counts and the
percentages of cells staining. The results are expressed as means  standard deviations, and significant differences from the HK-WT values are
indicated by an asterisk (P  0.05).
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function optimally due to lack of “background conditioning”
(27) by other helper T-cell responses.
The ELISPOT results (Fig. 8) thus suggest that other
epitopes may be emphasized in, particularly, the primary re-
sponse to these mutant viruses. We had not been using the
PB1-F262-70 (8) peptide because earlier experiments (unpub-
lished data) had indicated that the primary response to this
H2Db-restricted epitope is minimal. Analysis for the DbPB162-
specific set indicated that the sizes of the CD8 PB1-F262
 sets
in spleen (Fig. 9A) and BAL fluid (Fig. 9B) were not increased
following primary i.n. challenge with the HKNPPA virus.
However, the secondary response to DbPB162 was substantial
FIG. 5. Prevalence of IFN- TNF- CD8 KbPB1703
 and CD8 KbNS2114
 T cells in a secondary response. The mice were primed and
challenged as described in the legend to Fig. 1. The levels of TNF- and IFN- production were determined by intracellular cytokine staining
subsequent to peptide stimulation (see legend to Fig. 2), and the IFN- TNF-/IFN- ratios were determined for the BAL fluid and spleen
populations. The results are expressed as means standard deviations, and significant differences from the findings for the WT group are indicated
by an asterisk (P  0.05).
TABLE 3. Response in mice primed i.p. with the mutant viruses and then challenged i.n. with WT virusa
Virus Epitope
No. of tetramer CD8 T cells (mean  SD)
Expt 1 Expt 2
Spleen (106) BAL fluid (105) Spleen (105) BAL fluid (105)
WT (2) DbNP366 7.4  3.0 10  8.0 9.2  4.1 17 11
NP (1) 0.1  0.05* 0.09  0.07* 0.6  0.03* 0.02 0.02*
PA (2) 5.6  4.0 13  7.0 13.1  8 1.5 7.0
NPPA (1) 0.2  005* 0.1  0.07* 0.3  0.06* 0.1 0.03*
WT (2) DbPA224 1.2  0.7 1.1  0.7 2.4  0.7 2.0 0.7
NP (2) 0.7  0.3 3.6  3.0* 8.6  1.9* 0.7 0.9
PA (1) 0.08 0.07* 0.006  0.003* 0.2  0.09* 0.08 0.08
NPPA (1) 0.1  0.06* 0.003  0.002* 0.5  0.1* 0.1 0.04*
WT (2) KbPB1703 1.3  0.4 0.7  0.5 1.4  0.8 1.7 0.9
NP (2) 0.6  0.5 0.5  0.4 2.8  0.4 0.1 0.1*
PA (2) 0.3  0.3 0.2  0.1 1.1  0.9 0.6 0.4
NPPA (2) 1.3  0.5 0.2  0.1 2.1  0.9 1.4 0.7
WT (2) KbNS2114 0.3  0.1 0.3  0.2 0.3  0.1 1.2 0.9
NP (2) 0.1  0.08 0.2  0.1 1.6  0.5 0.08 0.09
PA (2) 0.1  0.1 1.0  1.2 0.8  0.4 0.3 0.2
NPPA (2) 1.1  0.08* 2.2  1.2* 1.6  0.7* 1.3 0.4
a B6 mice mice were primed i.p. with 108 EID50 of the PR WT and mutant (NP, PA, and NPPA) viruses and then challenged i.n. with 107 EID50 of the WT
HKx31 virus. The spleen and BAL fluid populations were harvested on day 9 (experiment 1) or day 8 (experiment 2). The mice in experiment 1 were challenged 2
months after priming, while those in experiment 2 were left for 7 months prior to challenge. The numbers in parentheses indicate the type of response generated for
each virus-specific epitope following the WT virus challenge. The numbers of tetramer CD8 T cells were calculated from the percentages of cells staining and the total
cell counts. Significant differences from the WT values are indicated as * (P 
 0.05).
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(Fig. 9C and D), indicating that this could explain the apparent
difference for the estimates of total size by the PepC (Fig. 7)
and ELISPOT (Fig. 8) assays. This apparent compensation in
the primary response (Fig. 8A) following i.n. challenge with the
HKNPPA virus is not, however, resolved by this analysis
with DbPB162 (Fig. 9A and B). One possibility is that other,
previously disregarded peptides may be involved following pri-
mary exposure (41). Future experiments will test the idea that
the range of a primary response can be expanded in the ab-
sence of prominent epitopes.
DISCUSSION
The absence of any obvious change in “quality” for the
enlarged CD8 KbPB1703
 and CD8 KbNS2114
 populations
that develop in the absence of the major DbNP366- and
DbPA224-specific sets could reflect that the functional capacity
of these T-cell sets is close to maximized in the normal infec-
tious process. The much smaller KbPB1703- and K
bNS2114-
specific T-cell populations generated in mice primed and
boosted with WT viruses already make high levels of IFN-
and TNF- following in vitro stimulation with peptide. There
was no evidence of any correlation between greater clonal
expansion and a lower-quality response in the acute phase
following secondary challenge.
Even so, the CD8 KbPB1703
 memory T cells sampled on
day 30 from the mice given the mutant viruses were making
less IFN- and TNF- than those from the WT prime-boost,
reversing the situation found for the day 10 BAL sample pop-
ulation specific for the same epitope. The change between the
acute response and memory is, however, unlikely to reflect
some TNF--mediated editing process, which has been shown
in previous experiments to operate only for the relatively small
numbers of T cells that have localized to the site of virus-induced
pathology (and high antigen load) in the infected lung (34, 39).
Also, this divergence in cytokine production for CD8
KbPB1703
 inflammatory (day 10 BAL sample) and memory (day
30 spleen) T cells was not replicated for the CD8 KbNS2114

response. Both in the sense of numerical compensation and in the
sense of induced cytokine expression profiles, T cells specific for
KbPB1703 and K
bNS2114 can behave differently.
FIG. 6. Intensity of IFN- and TNF- staining for peptide-stimulated CD8 KbPB1703
 and CD8 KbNS2114
 T cells. The MFI values are
shown for IFN- (A to D) and TNF- (E to H) in T cells from spleen (A, B, E, and F) and BAL samples (C, D, G, and H). The statistical analysis
compares values significantly different from those for the WT, and the asterisk denotes P  0.05.
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The overall conclusion from these experiments, and the less
extensive previous study (37), is that each epitope-specific
CD8-T-cell population has inherent characteristics that can
be varied only within certain limits. However, it is possible to
push responses to a higher level, at least in terms of the extent
of clonal expansion (12) and eventual numbers, such that re-
sidual T-cell sets can compensate fully for the loss of major
epitopes, at least following secondary challenge. There are
situations where it might be deemed advantageous to enhance
the potential for a particular CD8-T-cell response. What may
normally be a minor epitope on the surface of a virus-infected
(or tumor) cell (2) may, in fact, be a particularly useful target
for T-cell-mediated elimination. The question of what deter-
mines these immunodominance hierarchies needs to be an-
swered.
One possibility is that immunodominance may be a function
of the avidity of the interaction between the clonotypic TCRs
and antigenic peptide-MHCI complexes (23). If so, the rela-
FIG. 7. Comparison of the prevalence of epitope-specific and nonspecific CD8 T cells. The total CD8-cell counts (A and B) were subdivided
to compare the size of the virus-specific (C and D) IFN- CD8-T-cell sets from Table 1. (A and C) Spleen populations; (B and D) BAL sample
populations. The asterisk indicates P  0.05, where the NP, PA, and NPPA groups were compared to WT by a two-sided exact P value
for the two-sample Wilcoxon rank-sum test.
FIG. 8. ELISPOT analysis of the influenza virus-specific CD8-T-cell response. The total virus-specific response assay was performed following
primary (A) or secondary (B) infection with the WT, NP, PA, and NPPA influenza viruses. Purified CD8 splenocytes from infected mice
were incubated for 48 h with MHC class II/ (B6) and MHC class II/ (IAb/) APCs that were infected in vitro with WT HKx31 influenza
virus. The numbers of IFN--producing cells are expressed as spots per million CD8 T cells. The results are shown as means  standard errors
(n 	 4), and the asterisk indicates values that differed significantly from the WT result (P 
 0.05). The analysis was repeated (data not shown)
with comparable results.
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tionship between clonal expansion and TCR avidity may be an
inverse one. The DbNP366- and D
bPA224-specific responses are
equivalent in size following primary infection, but in excess of
10-fold-more CD8 DbNP366
 T cells are generated following
secondary challenge (25). This could in part reflect that the
DbPA224 epitope seems to be expressed mainly on dendritic
cells (DCs), while DbNP366 is found on a variety of cell types
including DCs and infected epithelium (9). Current experi-
ments are looking at the possibility that relocating the
PA224-233 peptide to the influenza virus neuraminidase stalk
(7) will change the profile of antigen expression, the quality of
the responding CD8 DbPA224
 T cells, and the relationship
between the secondary CD8 DbNP366
 and CD8 DbPA224

responses. The answers are not yet in, but it may be desirable
to repeat this type of analysis with the more minor PB1703-711,
NS2114-121, and PB1-F262-70 peptides.
It is clearly the case that there is no interaction (direct or
indirect) between different epitope-specific CD8-T-cell pop-
ulations following influenza virus infection of previously unex-
posed mice. Prior evidence suggests that the induction of pri-
mary CD8-T-cell responses is totally dependent on the
binding of naı¨ve precursors to antigen-presenting DCs over a
relative short time (35). Any primary response may thus be
considered to reflect the spectrum of epitope availability on
the DCs and, perhaps, the size of the potential TCR responder
repertoire. The fact that these minor responses increased in
magnitude following secondary challenge with mutant viruses
presumably reflects that the more readily triggered memory T
cells are responding to prolonged epitope expression on DCs
(and other cell types) as a consequence of delayed elimination
in the absence of the normally immunodominant effector T-
cell populations. Again, the interplay among antigen concen-
tration, antigen availability, TCR repertoire constraints, and
TCR epitope avidity presumably determines the ultimate mag-
nitude of the secondary response. It is worth establishing the
relative importance of these different components as we try to
develop CD8-T-cell–peptide-based vaccines to counter infec-
tious and, perhaps, oncogenic processes. The present experi-
ments define some of the baselines for moving such analyses
forward.
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